RxDoctor Payments Data

Ashutosh Sachdeva, MD

Pulmonary Disease · Baltimore, MDNPI 1902019078

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Ambu A/s at 37.4% of the total. Among pulmonary disease clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$101,725in general payments, 2019–2025

Across 252 payments — averaging $403.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ambu A/s$38K
  • Intuitive Surgical$16K
  • Cook Incorporated$13K
  • Fujifilm Healthcare Americas Corporation$4K
  • AstraZeneca$3K
  • Johnson & Johnson$3K
  • plus $25K from 28 others
$25,782in research payments, 2019–2025

Across 4 payments — averaging $6445.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Erbe Elektromedizin GmbH$24K
  • Gyrus ACMI, Inc.$1K
  • Spiration, Inc.$1K

What the payments were for

  • Consulting fees$56,01555%
  • Speaking & faculty fees$17,62017%
  • Travel & lodging$15,32915%
  • Food & beverage$8,7609%
  • Education$4,0004%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,725 in reported general payments places this provider in the 90th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Medicare billing

Part B allowed, 2024
$49,732
Medicare patients
164
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,616
Mycophenolate Mofetil11$526
Prednisone27$98
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$22

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →